ArticleBritish journal of cancer2015

Reply: Comment on 'Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'.

Andrew Rowland et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.